HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica

Abstract : Introduction: Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry. Case series: We report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild. Discussion: These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients, and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.
Document type :
Journal articles
Complete list of metadata

Contributor : Hal Sorbonne Université 5 Gestionnaire Connect in order to contact the contributor
Submitted on : Friday, January 14, 2022 - 11:53:55 AM
Last modification on : Friday, May 20, 2022 - 11:06:56 AM
Long-term archiving on: : Friday, April 15, 2022 - 6:39:11 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2022-07-14

Please log in to resquest access to the document



Edouard Januel, Jérôme de Seze, Patrick Vermersch, Elisabeth Maillart, Bertrand Bourre, et al.. Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Multiple Sclerosis Journal, SAGE Publications, 2021, pp.135245852110497. ⟨10.1177/13524585211049737⟩. ⟨hal-03526127⟩



Record views